Is it time for Brazil to prioritize TB preventive therapy for all people living with HIV?

Braz J Infect Dis. 2018 Jan-Feb;22(1):74-75. doi: 10.1016/j.bjid.2017.10.001. Epub 2017 Nov 6.

Authors

Ethel L Maciel¹, Thiago N do Prado², Kleydson Bonfim Andrade³, Jonathan E Golub⁴

Affiliations

¹ Universidade Federal do Espírito Santo (UFES), Laboratório de Epidemiologia (Lab-Epi), Vitória, ES, Brazil. Electronic address: ethel.maciel@gmail.com.
² Universidade Federal do Espírito Santo (UFES), Laboratório de Epidemiologia (Lab-Epi), Vitória, ES, Brazil.
³ Universidade de São Paulo, Faculdade de Saúde Pública, São Paulo, SP, Brazil.
⁴ Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Baltimore, United States.

No abstract available

Publication types

Letter

MeSH terms

Antitubercular Agents / therapeutic use
Brazil
HIV Infections / complications*
Humans
Isoniazid / therapeutic use
Latent Tuberculosis / prevention & control*
Preventive Health Services
Tuberculosis, Pulmonary / prevention & control*

Substances

Antitubercular Agents
Isoniazid